By


KaloCyte Closes Investment from New York Blood Center

This funding will be used to support KaloCyte as it scales up in advance of human trials

See more here

By


Eliksa Therapeutics launched with University of Utah’s commercial and clinical-stage regenerative medicine technology

Founding investors include Militia Hill Ventures and University of Utah

See more here

By


Renovacor Announces Pipeline Expansion with New Research Program for Multiple Genetic Segments of Arrhythmogenic Cardiomyopathy

Research collaboration with the University of Utah’s Nora Eccles Harrison Cardiovascular Research and Training Institute expands pipeline with the addition of an AAV gene therapy program for multiple genetic segments of arrhythmogenic cardiomyopathy

See more here

By


Annovis Bio Announces Positive FDA Notice For Buntanetap Phase 3 Clinical Trial In Parkinson’s Disease

FDA indicates the Company may proceed with the Phase 3 clinical study of buntanetap for the treatment of Parkinson’s disease

See more here

By


Immunome’s COVID-19 Cocktail Retains Neutralizing Activity Against the Most Prevalent Omicron Subvariants* in the US, BA.4/5 and BA.2.12.1

– IMM-BCP-01 neutralized BA.4/.5 and BA.2.12.1 subvariants in pseudovirus testing 

– IMM-BCP-01 currently in Phase 1b clinical testing with topline data expected in 2H 2022 

See more here

By


Bainbridge Health and Purdue University Collaborate to Advance the Infusion Pump Industry

Collaboration will form the leading infusion pump management platform and community in the United States

See more here

By


Annovis Bio Submits an International Patent Application to Cover the Treatment of Neurological Injuries Caused by Infections

Annovis Bio’s Current Intellectual Property Portfolio Covers the Use of Buntanetap, the Company’s Lead Compound, to Treat Neurodegenerative Diseases

With this Recent Filing, the Company Seeks Protection for Buntanetap to Treat Infection-Dependent Neurological Injuries

See more here

By


Immunome Announces Initiation of Phase 1b Study of IMM-BCP-01 for the Treatment of COVID-19

– First study subject has been dosed in a single dose/dose escalation study of recently diagnosed COVID-19 patients –

– Study will evaluate safety as the primary end point with pharmacokinetics (PK) and virology as secondary assessments –

See more here